MNTA - モメンタ・ファ―マシュ―ティカルズ (Momenta Pharmaceuticals Inc.) モメンタ・ファ―マシュ―ティカルズ

 MNTAのチャート


 MNTAの企業情報

symbol MNTA
会社名 Momenta Pharmaceuticals Inc (モメンタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 モメンタ・ ファーマシューティカルズ(Momenta Pharmaceuticals Inc)はバイオテクノロジー企業である。同社は腫瘍、自己免疫疾患用の薬、バイオシミラーおよび治療薬のジェネリックバージョンの開発に注力する。同社はLOVENOX(エノキサパリンナトリウム注射)およびCOPAXONE(酢酸グラチラマー注射)のジェネリック版を開発する。多発性硬化症の再発型の患者、炎症および神経変性を特徴とする中枢神経系の慢性疾患の治療のためのGLATOPA一日20mg/ミリリットルはジェネリックバージョンである。COPAXONEは1日1回で20mg/mL製剤と週3回40mg/mL製剤の両方で入手可能である。同社のエノキサパリンナトリウム注射剤は、深部静脈血栓症の予防および治療、および急性冠動脈症候群の治療を支援するためのLOVENOXのジェネリックバージョンである。同社のプログラムには、M254、M281およびM230が含まれる。   モメンタ・ファ―マシュ―ティカルズは複合分子の特性化・プロセス工学事業を行う米国バイオテクノロジ―企業。製品はエノキサパリンナトリウム注射剤はジェネテック版のロベノックス薬、酢酸塩ガラティラメル注射M356はジェネテック版のCopaxone、M923は自己免疫・炎症疾患のためのブランド生物製剤バイオシミラ―がある。   Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
本社所在地 301 Binney Street Cambridge MA 02142 USA
代表者氏名 Craig A. Wheeler Craig A. Wheeler
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-491-9700
設立年月日 37012
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 279人
url www.momentapharma.com
nasdaq_url https://www.nasdaq.com/symbol/mnta
adr_tso
EBITDA EBITDA(百万ドル) -133.07000
終値(lastsale) 20.26
時価総額(marketcap) 1586657199.68
時価総額 時価総額(百万ドル) 168.997
売上高 売上高(百万ドル) 106.58100
企業価値(EV) 企業価値(EV)(百万ドル) 758.16800
当期純利益 当期純利益(百万ドル) -136.94500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Momenta Pharmaceuticals Inc. revenues decreased 64% to $17.9M. Net loss increased 71% to $117.5M. Revenues reflect Product revenue decrease of 64% to $15.3M Research and development revenue decrease of 66% to $2.6M. Higher net loss reflects Other income - Balancing value decrease from $90K (income) to $574K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.96 to -$1.54.

 MNTAのテクニカル分析


 MNTAのニュース

   J&J finalizes Momenta Pharma buy (NYSE:JNJ)  2020/10/01 12:46:33 Seeking Alpha
Johnson & Johnson (NYSE:JNJ) has completed its $6.5B acquisition of Momenta Pharmaceuticals at $52.50 per common share. The deal was announced in August.
   Johnson & Johnson to Buy Drug Maker Momenta Pharmaceuticals for $6.5 Billion  2020/08/26 04:00:00 Thomasnet
It will reportedly be the largest pharma deal to date in 2020, topping Gilead’s $4.9 billion buy of Forty Seven.
   US stocks slide from record levels after Fed minutes reveal concern for economic recovery  2020/08/19 20:06:05 Business Insider
US stocks slid on Wednesday as investors mulled the cautionary remarks from Federal Reserve officials. Federal Open Market Committee meeting minutes showed policymakers fearing a slowdown in the economy's recovery. Members also refrained from issuing forward guidance on when it would enact new policies. The S&P 500 finished lower after reaching an intraday record high for a second straight day. On Tuesday, the benchmark index closed at its first all-time high since February. Investors also weighed signs of mild stimulus progress. House Speaker Nancy Pelosi suggested on Tuesday that Democrats might nix some facets of their proposal to expedite a relief package and reconsider passing those elements after November's elections. Oil slightly declined as new virus outbreaks abroad stoked demand worries. West Texas Intermediate crude slipped as much as 1.2%, to $42.36 per barrel. Watch major indexes update live here . US equities slid on Wednesday as wary remarks from the Federal Reserve's latest minutes overshadowed strong earnings reports.
   Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5 Billion in Cash  2020/08/19 17:40:00 Yahoo Finance
Johnson & Johnson (NYSE: JNJ) just took a big step into the field of immunology with a $6.5 billion deal for Momenta Pharmaceuticals (NASDAQ: MNTA). On Tuesday, the giant healthcare conglomerate announced a definitive agreement to acquire the biotech for $52.50 per share. The healthcare conglomerate is eager to expand its presence in Cambridge, Massachusetts, the world's leading hub for biopharmaceutical innovation and the location of Momenta's headquarters.
   Johnson & Johnson investit 6,5 milliards dans les maladies auto-immunes  2020/08/19 15:44:27 Les Echos
Le géant pharmaceutique américain va racheter la biotech Momenta Pharmaceuticals. Il s'agit du plus gros deal de l'année dans le secteur. La société, basée à Cambridge (Massachusetts), est spécialisée dans les maladies auto-immunes, comme Principia Biopharma rachetée lundi par Sanofi.
   Momenta's nipocalimab nabs Rare Pediatric Disease tag for anemia in newborns (NASDAQ:MNTA)  2020/07/28 12:31:08 Seeking Alpha
The FDA has signed off on Rare Pediatric Disease designation for Momenta Pharmaceuticals' (NASDAQ:MNTA) nipocalimab for the prevention of hemolytic disease
   Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN  2020/07/28 11:15:00 GlobeNewswire
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate,…
   Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)  2020/06/15 11:05:00 GlobeNewswire
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) - -…
   Why Is Momenta (MNTA) Down 0.6% Since Last Earnings Report?  2020/06/06 15:31:51 Zacks Investment Research
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Momenta (MNTA) Down 0.3% Since Last Earnings Report: Can It Rebound?  2020/03/27 15:30:53 Zacks Investment Research
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Momenta's nipocalimab nabs Rare Pediatric Disease tag for anemia in newborns (NASDAQ:MNTA)  2020/07/28 12:31:08 Seeking Alpha
The FDA has signed off on Rare Pediatric Disease designation for Momenta Pharmaceuticals' (NASDAQ:MNTA) nipocalimab for the prevention of hemolytic disease
   Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN  2020/07/28 11:15:00 GlobeNewswire
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate,…
   Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)  2020/06/15 11:05:00 GlobeNewswire
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) - -…
   Why Is Momenta (MNTA) Down 0.6% Since Last Earnings Report?  2020/06/06 15:31:51 Zacks Investment Research
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Momenta (MNTA) Down 0.3% Since Last Earnings Report: Can It Rebound?  2020/03/27 15:30:53 Zacks Investment Research
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 モメンタ・ファ―マシュ―ティカルズ MNTA Momenta Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)